Rakuten Medical funnels 95% of its resources into U.S. 'lightsaber' cancer fight
CEO Minami Maeda is running Phase 3 trials and targeting a 2028 FDA submission as photoimmunotherapy moves from Japanese clinics toward the world's largest market.
By Hessa Al-Faleh·· 3 min